What are the key agreements established in connection with Medline's IPO?

In connection with the IPO, Medline entered into several material definitive agreements. These include the Second Amended and Restated Limited Partnership Agreement of Medline Holdings, the Tax Receivable Agreement, the Exchange Agreement, and the Registration Rights Agreement. Additionally, Director Nomination Agreements were made with significant investors like Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC, and the Mills Family, along with an Information and Access Agreement with Hux Investment Pte. Ltd.

How were the proceeds from the IPO utilized?

The IPO generated significant proceeds. A substantial portion of the funds from the issuance of 179,000,000 shares was used to purchase an equivalent number of newly issued Common Units from Medline Holdings. Medline Holdings then used these funds to repay its New Euro Term Loan Facility in full and a portion of its 2028 Refinancing Term Loan Facility. The remaining proceeds were allocated for general corporate purposes and to cover offering expenses. Additionally, proceeds from shares issued under the underwriters' option were used to purchase or redeem shares and common units from certain pre-IPO owners.

What changes were made to Medline's corporate structure and governance as a result of these filings?

The filing indicates that Medline's Amended and Restated Certificate of Incorporation and Bylaws became effective on December 16, 2025. The Certificate of Incorporation establishes a significant authorized capital stock structure, including 50 billion shares of Class A common stock, 50 billion shares of Class B common stock, and 5 billion shares of preferred stock. The appointment of Todd M. Bluedorn to the Board of Directors and Audit Committee, along with the adoption of the 2025 Omnibus Incentive Plan and 2025 Employee Stock Purchase Plan, also signify key governance and compensation framework updates.

Are there any implications of the Tax Receivable Agreement for investors?

The Tax Receivable Agreement is designed to generally require Medline to pay to the existing owners of Medline Holdings a portion of the benefits Medline may realize from future increases in the tax basis of the assets of Medline Holdings and its subsidiaries resulting from certain exchanges of common units for cash or shares of Class A common stock, and from certain other transactions. Investors should review the details of this agreement, as described in the Prospectus and incorporated by reference, to understand potential future cash outflows and their impact on the company's financial performance and liquidity.

MDLN 8-K: Leadership Changes, Material Agreements & More

Summary

Medline Inc. (MDLN) filed an 8-K report on December 22, 2025, detailing key events surrounding its initial public offering (IPO) on December 16, 2025. The filing primarily concerns the execution of material definitive agreements essential for its transition to a publicly traded company. These agreements establish the operational and governance framework post-IPO, including the Medline Holdings Limited Partnership Agreement, a Tax Receivable Agreement, an Exchange Agreement, and a Registration Rights Agreement. Furthermore, the report announces the appointment of Todd M. Bluedorn to the Board of Directors and his role on the Audit Committee, including an RSU award. The company also formally adopted its 2025 Omnibus Incentive Plan and 2025 Employee Stock Purchase Plan. The amended Certificate of Incorporation and Bylaws, effective December 16, 2025, outline the authorized capital stock structure. Notably, the company successfully completed its IPO, issuing 248,439,654 shares of Class A Common Stock at $29.00 per share, generating significant proceeds used for debt repayment and strategic acquisitions of common units from pre-IPO owners.

Key Highlights

1Medline Inc. completed its initial public offering (IPO) of Class A common stock on December 16, 2025, issuing 248,439,654 shares at $29.00 per share.
2Significant agreements were executed in connection with the IPO, including the Medline Holdings Limited Partnership Agreement, Tax Receivable Agreement, and Exchange Agreement.
3Director Nomination Agreements were established with key pre-IPO investors including Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC, and the Mills Family.
4Todd M. Bluedorn was appointed to the Board of Directors and the Audit Committee, receiving a $300,000 RSU award.
5The company adopted the Medline Inc. 2025 Omnibus Incentive Plan and the 2025 Employee Stock Purchase Plan.
6The Amended and Restated Certificate of Incorporation authorizes 50 billion shares each of Class A and Class B common stock, and 5 billion shares of preferred stock.
7IPO proceeds were primarily used to repay outstanding indebtedness under the New Euro Term Loan Facility and the 2028 Refinancing Term Loan Facility, with the remainder for general corporate purposes and offering expenses.

Medline Inc. 8-K Report, Material Agreement (Dec 22, 2025)

Summary

Key Highlights

Frequently Asked Questions